The multi-year agreement stipulates that the distributor must meet a defined set of sales performance criteria. NIR Diagnostics is currently not disclosing the name of the distributor pending the completion of negotiations with North American medical device companies also interested in distribution rights to HemoNIR.
Duncan MacIntyre, president, CEO and executive vice chairman of NIR Diagnostics, said: “The accuracy and ease-of-use of our technology as well as the broad range of monitoring options arising from both our in-vitro and in-vivo platforms is driving renewed interest in HemoNIR.”